Erin Mershon

Senior Washington Correspondent

Erin Mershon covers the politics and policy of health care for STAT in Washington. She's written extensively on those and other policymaking issues for CQ Roll Call, Politico Pro, the National Journal and several other news outlets. A graduate of Kenyon College in Ohio, Erin won a 2017 Association of Health Care Journalists Fellowship to report on health insurance challenges in rural areas across the U.S. When she's not roaming the Capitol basements, Erin is usually indulging her obsession with ballet, either at a Kennedy Center performance or a beginner class.

Politics

Erin Mershon

Senior Washington Correspondent

HHS opens door to possibility of importing some drugs to drive down prices

FDA’s Gottlieb slams drug makers for stalling release of biosimilars

Appeals court rejects hospital industry’s challenge on 340B changes

What Pfizer, Trump, and consumers got out of a surprising deal — and what they didn’t

In subtle mixing of messages, the drug industry tries to press Congress to lift burden for more drug costs

Azar makes case for revamping hospital drug discounts — to hospitals defending them

Top Democrat demands PhRMA, BIO do more on gender issues after party with topless dancers

Mass. gets a thumbs-down on negotiating Medicaid prices, but Oklahoma wins on ‘value’ rebates

As the drug industry eyes the burgeoning biosimilar market, its united front is starting to crack

Key lawmaker calls for more scrutiny of hospitals using drug discount program — but no broader changes

Bill to encourage generic-drug development passes a key hurdle

Azar says HHS could change or eliminate Medicare drug rebates without Congress

Drug makers considering ‘substantial’ decreases in prices, Azar says

Drug pricing advocates take aim at Democrats for supporting pharma

Momentum grows to resurrect legislation aimed at bringing generic drugs to market faster

As CAR-T treatments advance, Washington grapples with ideas for how to pay for them

‘Right-to-try’ law intended to weaken the FDA, measure’s sponsor says in blunt remarks

Drug makers push back on cost-effectiveness research for Medicare drugs

Erin Mershon

Senior Washington Correspondent

Sign up for our Morning Rounds newsletter